Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health Care Team
Printable Schedule-at-a-Glance (Updated: 03/14/2018)
MONDAY, APRIL 16, 2018 — Up to 6.75 continuing education credits available.
ACPE UAN 0860-0000-18-002-L01-P/0860-0000-18-002-L01-T (.675 CEUs)
Registration and Continental Breakfast
Welcome and Opening Remarks
What’s New in Organ Allocation and Distribution, Timothy L. Pruett, MD, University of Minnesota Health
Changes in organ allocation policies were intended to decrease waitlist mortality rates and increase organ availability for ill patients. Despite these changes, however, disparities still exist. This session will address how national policy impacts transplant access and organ availability and discuss the challenges of organ donation, access, and distribution.
Living Donation: Risks, Benefits and Long-Term Outcomes, Amit D. Tevar, MD, University of Pittsburgh Medical Center
Living organ donation clearly saves lives and presents an opportunity to help address the critical need for organ transplants. In some circumstances it reduces recipients’ waiting times and increases opportunities for patients without living donors to receive organs from deceased donors. There are, however, a series of ethical questions that arise with living donation that need to be addressed. This session will discuss the ethical issues surrounding living donation, including the risks, benefits and long-term outcomes for living donors.
Options for Advanced Heart Failure: Transplantation, Total Artificial Hearts and Mechanical Circulatory Support, Jaime D. Moriguchi, MD, Cedars-Sinai Heart Institute
Heart transplantation is the only curative therapy for chronic heart failure. However, the shortage of appropriate donor organs and the expanding pool of patients waiting for heart transplantation have led to growing interest in alternative strategies, including left-ventricular-assist-device (LVAD) therapy and total artificial hearts (TAHs). This session will describe the clinical use and long-term outcome of LVADs and discuss the challenges with assist devices as alternatives to transplantation. The use of the TAH as a bridge to transplant will also be reviewed
Lung Transplantation: Moving Towards a New Standard of Care, Gabriel Loor, MD, FACC, Baylor St. Luke's Medical Center
Lung transplantation has become standard therapy for patients with severe end-stage lung disease and pulmonary vascular disease. This session will discuss the epidemiology of lung transplant, donor selection, immunosuppressive therapies and complications of lung transplant. The standard of care will also be reviewed.
Luncheon Presentation — An Overview of Optum® (nonaccredited/optional; lunch provided)
Exhibit Hall Grand Opening Dessert Reception — Exhibits Open
Precision Medicine in Cancer Care, Jonathan C. Trent, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami Health System
Precision medicine is defined by the tailoring of medical treatment to the individual characteristics of each patient and his/her disease. This session will discuss the role of precision medicine in cancer and highlight milestones in cancer therapy.
The Opioid Crisis and Its Effect on Transplant, Gregory J. McKenna, MD, FRCS(C), FACS, Baylor Scott & White Health
Organ donations have increased in the wake of America’s opioid epidemic. This session will address the opioid crisis and its effect on organ donation and transplantation.
The Future of Immunosuppression in Transplantation, Robert C. Harland, MD, FACS, Banner University Medical Center-Tucson
The guiding principle with immunosuppression in solid organ transplants is to achieve a balance between preventing rejection and avoiding side effects, which include various common and opportunistic infections and malignancies. This session will include a summary of immunosuppression and its future application in transplantation.
Current Disquiets of a Liver Transplant Surgeon, Michael Abecassis, MD, MBA, Northwestern University
This session will provide a glimpse into the thoughts, challenges and questions that occupy a transplant surgeon‘s mind as he or she continues to serve a growing population in need of organ transplantation.
Complimentary Get-Acquainted Reception — Exhibits Open
TUESDAY, APRIL 17, 2018 — Up to 5.75 continuing education credits available.
ACPE UAN 0860-0000-18-003-L01-P/0860-0000-18-003-L01-T (.575 CEUs)
Registration and Continental Breakfast — Exhibits Open
Treatment Strategies for Acute Lymphoblastic Leukemia: From Adolescents to Adults, Michael Verneris, MD, Children's Hospital Colorado
Acute lymphoblastic leukemia (ALL) is a disease that affects infants, children, adolescents and adult patients. Adolescents and young adults (AYAs) with ALL pose unique challenges and issues beyond those faced by adults. This session will discuss therapies used to treat ALL in both AYAs and adults and highlight treatment strategies for both newly diagnosed and relapsed/refractory ALL in AYA and adult populations.
Improving Safety of Allotransplantation: Current and Emerging Strategies for the Prevention of Graft-versus-Host Disease, Nandita Khera, MD, MPH, Mayo Clinic
Graft-versus-host disease (GvHD) represents the most serious and challenging complication of allogeneic hematopoietic stem-cell transplantation (HSCT). This session will discuss its pathophysiology, assessment of patient risk for GvHD, diagnostic challenges, management recommendations, prevention and emerging therapeutic treatment options.
Break — Exhibits Open
New Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy, Kara Davis, DO, The Lucile Salter Packard Children's Hospital
Early outcomes from CAR T-cell trials have generated impressive results in patients with blood cancers. Clinical trials of CAR T-cell therapy have involved pediatric and adult patients with blood-based cancers, such as leukemia and lymphoma. Pipeline therapeutics are in early stages of development. This session will discuss the latest advances in CAR T-cell therapies and promising pipeline therapeutics.
Infectious Disease in Blood/Marrow Transplantation, Sanjeet S. Dadwal, MD, FACP, City of Hope
Certain factors place individuals undergoing a blood/marrow transplant (BMT) at increased risk for infections. Despite recent advances in supportive care, growth factors, more-potent antimicrobials, prophylaxis strategies, and new diagnostic techniques, infections remain the major causes of mortality in individuals who undergo a BMT.
The Impact of Timely Referrals for Blood/Marrow Transplantation on Patient Outcomes and Transplant Success, Linda J. Burns, MD, National Marrow Donor Program/Be The Match
Studies on blood/marrow transplantation (BMT) have revealed that transplant success can be highly dependent upon transplant timing. Early referral is a critical factor for optimal transplant outcomes. This session will discuss referral timing guidelines and highlight disease categories that include patients at risk for disease progression. The impact of timely referrals on the outcomes and success of BMT will also be discussed.
Therapeutic Strategies in the Treatment of Hodgkin Lymphoma, Matthew Lunning, DO, University of Nebraska Medical Center
Treatment of Hodgkin lymphoma is tailored to disease type, disease stage and an assessment of the risk of resistant disease. The current treatment of Hodgkin lymphoma seeks to maximize the risk-benefit ratio of treatment. This session will discuss therapeutic strategies in the treatment of Hodgkin lymphoma with a focus on tailoring therapy to each patient according to age and his/her risk of short- and long-term toxicity and/or relapse.
The Continuum of Chronic Kidney Disease to End-Stage-Renal Disease, Frank C. Brosius, MD, University of Arizona
Chronic kidney disease (CKD) is increasingly recognized as a major public health problem and leads to irreversible kidney damage that can further progress to end-stage-renal disease (ESRD). Careful monitoring and timely evaluations of individuals with CKD are essential to improve survival and quality of life, as well as prevent ESRD. This session will discuss how underlying kidney disease and other key factors can influence the progression of CKD to ESRD. Indications for renal replacement therapy will also be addressed.
Note: OptumHealth Education reserves the right to make any necessary changes to this program. Efforts will be made to keep presentations as scheduled. However, unforeseen circumstances may result in the substitution of faculty or content.
Last updated: 03/14/18